skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

High content screening for nonclassical peroxisome proliferators

Original Research

(1433) Views  (610) Full article downloads

Authors: Jonathan Z Sexton, Qingping He, Lawrence J Forsberg, et al

Published Date July 2010 Volume 2010:1 Pages 127 - 140
DOI: http://dx.doi.org/10.2147/IJHTS.S10547

Jonathan Z Sexton1,2, Qingping He1, Lawrence J Forsberg3, Jay E Brenman3,4

1Biomanufacturing Research Institute and Technology Enterprise (BRITE), North Carolina Central University, 2Department of Pharmaceutical Sciences, North Carolina Central University, 3The Neuroscience Center UNC Chapel Hill School of Medicine, 4Cell and Developmental Biology Dept UNC-CH School of Medicine

Abstract: Peroxisomes are ubiquitous cellular organelles that perform vital functions ­including fatty acid beta-oxidation, plasmalogen synthesis, and detoxification of harmful oxidative ­species. In rodents numerous compounds that increase peroxisome biogenesis also alleviate metabolic syndrome (MetS)/type 2 diabetes (T2D) symptoms. However, compounds that increase peroxisome biogenesis in rodents largely do not increase peroxisome biogenesis in humans. We designed a novel genetically encoded high throughput screening (HTS) high content assay to identify small molecule compounds that function as peroxisome proliferators in human cells. From this assay we have confirmed that 4-phenylbutyrate (PBA), a PPAR independent peroxisome proliferator and chemical chaperone, increases peroxisome proliferation in human cells and serves as a positive control for our screen. We performed a small pilot and larger 15,000 compound production screen with an overall Z’ factor of 0.74 for 384-well plate format, providing a valuable screening tool for identifying peroxisome modulator compounds. From this screen we have identified 4 existing drugs and 10 novel compounds, some with common scaffolds 1000X more potent than PBA. It is hoped that these novel compounds may serve as scaffolds for testing for efficacy in alleviating MetS/T2D symptoms both in mouse models and ultimately human disease.

Keywords: high-content screening, high-content analysis, peroxisome biogenesis, diabetes, metabolic syndrome, 4-phenylbutyrate






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Open access liquid chromatography/tandem mass spectrometry: implementation of a fully quantitative system in a drug discovery laboratory
Computational characterization of SAR microenvironments in high-throughput screening data
Cell line and drug-dependent effect of ERBB3 on cancer cell proliferation, chemosensitivity, and multidrug actions
Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway
New developments and emerging trends in high-throughput screening methods for lead compound identification
Fission yeast as a HTS platform for molecular probes of HIV-1 Vpr-induced cell death
Optimal management of familial hypercholesterolemia: treatment and management strategies
Diabetic microvascular complications: possible targets for improved macrovascular outcomes
The development of a high-throughput/ combinatorial workflow for the study of porous polymer networks
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio